| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $44.9M | +92.3% | +222.8% |
| SG&A Expense | $4.6M | +3.3% | +5.1% |
| Operating Income | -$49.5M | -78.1% | -171.0% |
| Income Tax | $0 | — | — |
| Net Income | -$47.7M | -82.2% | -207.8% |
| EPS (Basic) | -$0.61 | -48.8% | -154.2% |
| EPS (Diluted) | -$0.61 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $90.1M | +337.8% | +157.1% |
| Current Assets | $183.2M | +25.9% | -14.1% |
| Total Assets | $187.3M | +24.9% | -14.5% |
| Current Liabilities | $45.1M | +69.3% | +177.0% |
| Total Liabilities | $48.3M | +60.3% | +134.3% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Capital Expenditures | $91K | — | — |
| -154.2% |
| $139.0M |
| +16.0% |
| -29.9% |